Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
June 20, 2018
Geneva, Switzerland and Boston, MA – June 20, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read morepress release
June 18, 2018
Geneva, Switzerland and Boston, MA – June 18, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…
Read morepress release
Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being…
Read moreMay 8, 2019
May 9, 2018
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840